Taiwan MS patients monitored for fingolimod side effects

NCT ID NCT04480853

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This study watches for side effects in 30 Taiwanese adults with relapsing-remitting multiple sclerosis who are starting fingolimod. It does not test a new treatment but collects safety data over one year. Participants must not have used fingolimod before and must meet other health criteria.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Kaohsiung City, 83301, Taiwan
Novartis Investigative Site
RECRUITING

Taichung, 407219, Taiwan
Novartis Investigative Site
WITHDRAWN

Tainan, 704302, Taiwan
Novartis Investigative Site
RECRUITING

Taipei, 10002, Taiwan
Novartis Investigative Site
WITHDRAWN

Taipei, 11220, Taiwan
Novartis Investigative Site
WITHDRAWN

Taoyuan, 33305, Taiwan

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS